Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications : vimarsana.com

04.11.2023 - TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today presented additional Phase 1 clinical data ... Seite 1

Related Keywords

Texas , United States , Sapna Patel , Stevenc Katz , Trisalus Life Sciences Inc , University Of Texas Md Anderson Cancer Center , Society Of Immunotherapy , Nasdaq , Trinav Infusion System , Progression Free Survival , Disease Control Rate , Chief Medical Officer ,